Recent and Upcoming Drug Therapies for Pediatric Heart Failure
Pediatric heart failure (HF) is an important clinical condition with high morbidity, mortality, and costs. Due to the heterogeneity in clinical presentation and etiologies, the development of therapeutic strategies is more challenging in children than adults. Most guidelines recommending drug therap...
Main Authors: | Karla L. Loss, Robert E. Shaddy, Paul F. Kantor |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-11-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2021.681224/full |
Similar Items
-
Does sacubitril/valsartan work in children with heart failure?—a pilot study
by: Yahe Xu, et al.
Published: (2023-11-01) -
Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
by: Chih‐Yuan Niu, et al.
Published: (2022-09-01) -
Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments
by: Matthias Naegele, et al.
Published: (2016-02-01) -
The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population
by: Giuseppe Dattilo, et al.
Published: (2023-09-01) -
Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
by: Makiko Nakamura, et al.
Published: (2023-06-01)